Bio-prospecting

Bio-prospecting is the systematic exploration of biodiversity and genetic resources to discover commercially valuable genes, compounds, or biological properties for developing new products in pharmaceuticals, agriculture, or cosmetics. The concept is governed by the UN Convention on Biological Diversity (CBD) and its Nagoya Protocol, which were established to prevent 'biopiracy'. These frameworks mandate that users of genetic resources must comply with the laws of the provider country. Key principles include obtaining Prior Informed Consent (PIC) from the competent national authority and establishing Mutually Agreed Terms (MAT) with the provider to ensure the Fair and Equitable Sharing of Benefits (ABS). In enterprise risk management, non-compliance with ABS principles constitutes a major intellectual property and legal risk, potentially leading to patent invalidation, international sanctions, and substantial financial penalties.

Enterprises must integrate bio-prospecting compliance into their R&D and supply chain risk management frameworks. Key steps include: 1. Due Diligence: Before initiating a project, identify the country of origin for all biological materials and verify its status as a party to the Nagoya Protocol and its domestic ABS laws. 2. Establish Compliance Procedures: Develop Standard Operating Procedures (SOPs) requiring researchers to secure PIC and sign a legally binding MAT contract before accessing materials, specifying benefit-sharing mechanisms like royalties or technology transfer. 3. Documentation and Monitoring: Implement a tracking system, aligned with compliance management standards like ISO 37301, to maintain all PIC, MAT, and benefit-sharing records, ensuring full supply chain traceability. For example, a global cosmetics firm must present a benefit-sharing agreement with an indigenous community to legally market a product using their local plant extract in the EU, thereby achieving 100% compliance and mitigating supply chain disruption risks.

Taiwanese enterprises face three primary challenges in implementing bio-prospecting compliance: 1. Lack of Regulatory Awareness: Many R&D-focused SMEs are unfamiliar with the extraterritorial reach of the Nagoya Protocol, leading to unintentional non-compliance when commercializing resources obtained through academic channels. 2. Opaque Supply Chains: It is often difficult to trace the origin of raw materials from suppliers and verify their legal acquisition, creating hidden compliance risks. 3. Limited Cross-Border Negotiation Experience: Companies often lack the expertise to negotiate complex MATs with foreign governments or indigenous communities, putting them at a disadvantage due to legal and cultural differences. To overcome these, firms should conduct internal training on ABS regulations (3-month timeline), update supplier contracts to mandate ABS compliance documentation (6-month timeline), and engage expert legal consultants for high-risk projects to secure their interests.

Winners Consulting specializes in Bio-prospecting for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact